Fubotv earnings beat by $0.10, revenue topped estimates
Jeffrey W. Dunn, a director at SI-BONE, Inc. (NASDAQ:SIBN), sold 293 shares of common stock on August 4, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The transaction comes as the medical device company’s stock has declined over 10% in the past week, though it maintains a strong financial health score according to InvestingPro data. The shares were sold at a weighted average price of $17.3743, with individual sales prices ranging from $17.36 to $17.39, for a total transaction value of $5,090. Despite recent price volatility, SI-BONE demonstrates solid fundamentals with a healthy current ratio of 8.38 and impressive revenue growth of nearly 23% over the last twelve months.
Following the transaction, Dunn directly owns 11,647 shares of SI-BONE, Inc. common stock, which includes 11,124 shares issuable on the settlement of restricted stock units. He also indirectly owns 117,827 shares through The Jeffrey W. Dunn Living Trust Dated May 17, 2012.
The sale reported on the Form 4 represents shares required to be sold by Dunn to cover tax withholding obligations in connection with the vesting of restricted stock units. The filing indicates that the sale satisfies tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by Dunn.
In other recent news, SI-BONE Inc. reported strong second-quarter earnings, exceeding both revenue and earnings expectations. The company achieved revenue of $48.6 million, surpassing the forecasted $46.72 million, and marking a 22% growth compared to the previous year. Additionally, SI-BONE reported an earnings per share (EPS) of -$0.14, beating analyst predictions of -$0.18, which represents a 22.22% surprise. Analysts have responded positively to these results, with Canaccord Genuity raising its price target for SI-BONE to $26 and maintaining a Buy rating. Similarly, Jefferies increased its price target to $28, also maintaining a Buy rating, citing the strong quarterly performance. The company achieved positive adjusted EBITDA for the third consecutive quarter and reported cash flow positivity earlier than expected. U.S. revenue specifically grew by 23% during the quarter, further highlighting the company’s solid performance. These developments reflect SI-BONE’s continued progress and favorable reception among analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.